HIV-infected patients with lipodystrophy have higher rates of carotid atherosclerosis:: The role of monocyte chemoattractant protein-1

被引:43
作者
Coll, Blai [1 ]
Parra, Sandra
Alonso-Villaverde, Carlos
de Groot, Eric
Aragones, Gerard
Montero, Manuel
Tous, Monica
Camps, Jordi
Joven, Jorge
Masana, Lluis
机构
[1] Hosp Univ Sant Joan, Serv Med Interna, Reus, Spain
[2] Hosp Univ St Joan, Ctr Rec Biomed, Reus, Spain
[3] Hosp Univ St Joan, Serv Radiol, Reus, Spain
[4] Amsterdam Med Ctr, Vasc Med Dept, Amsterdam, Netherlands
关键词
MCP-1; sub-clinical atherosclerosis; lipodystrophy; HIV; inflammation;
D O I
10.1016/j.cyto.2006.03.013
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Individuals with HIV-1 infection are at increased risk for cardiovascular events, and lipodystrophy is generally associated with proatheroizenic metabolic disturbances. We conducted a case-control study to assess the presence of sub-clinical atherosclerosis in HIV-1-infected patients with or without lipodystrophy (LD) and to evaluate the influence of monocyte chemoattractant protein-1 (MCP-1) on the development of both carotid atherosclerosis and LD. The study population consisted of 43 patients with LD and 86 patients without LD. We determined carotid intima-media thickness (IMT), MCP-1 concentrations in plasma, and MCP-1 genotype (presence or absence of the -2518G allele). HIV-1-infected patients with LD showed increased risk (OR = 3.71, 95% CI = 1.10-12.47, p = 0.03) for sub-clinical atherosclerosis. and MCP-1 plasma concentration was significantly correlated with IMT in these patients (Pearson - 0.31, p = 0.03). Furthermore. presence of LD was a determinant for MCP-1 plasma concentration (beta = 0.18, p = 0.05). In summary, HIV-1-infected patients with clinically manifest LD are at higher risk for atherosclerosis and our observations support the relationship between inflammation and atherosclerotic disease. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:51 / 55
页数:5
相关论文
共 21 条
  • [1] Atherosclerosis in patients infected with HIV is influenced by a mutant monocyte chemoattractant protein-1 allele
    Alonso-Villaverde, C
    Coll, B
    Parra, S
    Montero, M
    Calvo, N
    Tous, M
    Joven, J
    Masana, L
    [J]. CIRCULATION, 2004, 110 (15) : 2204 - 2209
  • [2] Monocyte chemoattractant protein-1 release is higher in visceral than subcutaneous human adipose tissue (AT): Implication of macrophages resident in the AT
    Bruun, JM
    Lihn, AS
    Pedersen, SB
    Richelsen, B
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (04) : 2282 - 2289
  • [3] Monocyte chemoattractant protein-1 is produced in isolated adipocytes, associated with adiposity and reduced after weight loss in morbid obese subjects
    Christiansen, T
    Richelsen, B
    Bruun, JM
    [J]. INTERNATIONAL JOURNAL OF OBESITY, 2005, 29 (01) : 146 - 150
  • [4] Carotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure
    Currier, JS
    Kendall, MA
    Zackin, R
    Henry, WK
    Alston-Smith, B
    Torriani, FJ
    Schouten, J
    Mickelberg, K
    Li, YJ
    Hodis, HN
    [J]. AIDS, 2005, 19 (09) : 927 - 933
  • [5] B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: A report of the regression growth evaluation statin study (REGRESS)
    de Groot, E
    Jukema, JW
    van Swijndregt, ADM
    Zwinderman, AH
    Ackerstaff, RGA
    van der Steen, AFW
    Bom, N
    Lie, KI
    Bruschke, AVG
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 31 (07) : 1561 - 1567
  • [6] Molecular mechanisms mediating inflammation in vascular disease - Special reference to monocyte chemoattractant protein-1
    Egashira, K
    [J]. HYPERTENSION, 2003, 41 (03) : 834 - 841
  • [7] Cardiovascular disease risk factors in HIV patients -: association with antiretroviral therapy.: Results from the DAD study
    Friis-Moller, N
    Weber, R
    Reiss, P
    Thiébaut, R
    Kirk, O
    Monforte, AD
    Pradier, C
    Morfeldt, L
    Mateu, S
    Law, M
    El-Sadr, W
    De Wit, S
    Sabin, CA
    Phillips, AN
    Lundgren, JD
    [J]. AIDS, 2003, 17 (08) : 1179 - 1193
  • [8] Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report
    Grundy, SM
    Becker, D
    Clark, LT
    Cooper, RS
    Denke, MA
    Howard, WJ
    Hunninghake, DB
    Illingworth, R
    Luepker, RV
    McBride, P
    McKenney, JM
    Pasternak, RC
    Stone, NJ
    Van Horn, L
    Brewer, HB
    Cleeman, JI
    Ernst, ND
    Gordon, D
    Levy, D
    Rifkind, B
    Rossouw, JE
    Savage, P
    Haffner, SM
    Orloff, DG
    Proschan, MA
    Schwartz, JS
    Sempos, CT
    Shero, ST
    Murray, EZ
    Keller, SA
    Jehle, AJ
    [J]. CIRCULATION, 2002, 106 (25) : 3143 - 3421
  • [9] HMG-CoA reductase inhibition reduces monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1-mediated monocyte recruitment in vivo
    Han, KH
    Ryu, J
    Hong, KH
    Ko, JS
    Pak, YK
    Kim, JB
    Park, SW
    Kim, JJ
    [J]. CIRCULATION, 2005, 111 (11) : 1439 - 1447
  • [10] Kastelein John J P, 2004, Am J Med, V116 Suppl 6A, p31S